CC BY
6Материалы всероссийского научного форума студентов с международным участием «СТУДЕНЧЕСКАЯ НАУКА - 2020» 275
severe acute respiratory syndrome (SARS) vs.
MIDDLE EAST RESpIRAToRY SYNDRoME (MERS)
Yakovlev A.
Scientific Supervisor: Senior Lecturer Daineko Maria Yurievna
Department of Foreign Languages
Saint Petersburg State Pediatric Medical University
Contact information: Yakovlev A. E-mail: mariadaineko@gmail.com
Key words: severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), viral pneumonia, acute respiratory disease syndrome (ARDS).
Research Relevance: SARS and MERS are zoonoses etiologically related to SARS-CoV and MERS-CoV, respectively. The natural reservoir of SARS-CoV is bats, while for MERS-CoV they are single-humped camels. Infection occurs when poorly cooked meat of these animals is eaten. As a result, a mutated virus acquires the ability to cause the disease in humans [3].
Objective: to analyze the suggestions of a possible association between SARS-CoV and MERS-CoV infections and the development of extra-respiratory symptoms, including damage to the central nervous system and gastrointestinal tract.
Materials and Methods: The following sources of information were used: the PubMed database which comprises more than 30 million citations for biomedical literature from Medline, life science journals, and online books.
Results: The received results clearly demonstrated that different for these two infections is the rate of development of severe viral pneumonia, and, as a result, acute respiratory disease syndrome (ARDS). In the case of SARS, pneumonia develops in 10-20% of patients on days 5-7 from the onset of the disease, and ARDS on days 3-5 of pneumonia. With MERS, the disease often makes a debut with severe viral pneumonia from the very first days, and the mortality rate of MERS-CoV infection is 36% [1,2].
Conclusion: Prevention of infections with a tendency to pandemic is always much more effective than treatment. At present, specific prevention of coronavirus infection (including especially dangerous SARS and MERS) has not been developed. References
1. Monika Jevsnik, Tina Ursic, Nina Zigon et al. Coronavirus infections in hospitalized pediatric patients with acute respiratory tract disease. BMC Infectious Diseases. 2012.
2. Aleksandra Szczawinska-Poplonyk, Katarzyna Jonczyk-Potoczna et al. Fatal respiratory distress syndrome due to coronavirus infection in a child with severe combined immunodeficiency. 2012.
3. И.И. Могилева, И.Л. Гальфанович, М.Ю. Дайнеко, Н.В. Жуковская, В.А. Кузина, Н.А. Нудельман, М.П. Слободчикова, Л.М. Тюмина, И.Е. Бранис. Infectious Diseases of Childhood. Учебное пособие. СПбГПМУ. 2019.
le placebo à l'hôpital
Zavyalova E. D.
Directeur: professeur de français Bok Elena Yurievna Département des langues étrangères
Université d'Etat de pédiatrie et de médecine générale de Saint-Pétersbourg
Contact information: Zavyalova Ekaterina Dmitrievna, 1st year student of medical faculty. E-mail: zavyalova.ecaterina@yandex.ru
Mots clé: placebo, l'utilisation, les avantages et les inconvénients, professionnels insuffisamment informés.
forcipe
том 3 СПЕЦВЫПУСК 2020
eISSN 2658-4182
